High-dose therapy and autologous stem cell transplantation for chemoresistant Hodgkin lymphoma: the Seattle experience.

Publication Type:

Journal Article

Source:

Cancer, Volume 113, Issue 6, p.1344-50 (2008)

Keywords:

2008, Antineoplastic Combined Chemotherapy Protocols, Center-Authored Paper, Clinical Research Division, Drug Resistance, Neoplasm, Female, hematopoietic stem cell transplantation, Hodgkin Disease, Humans, Male, Middle Aged, Neoplasm Staging, Research Trials Office Core Facility - Biostatistics Service, Salvage Therapy, Shared Resources, Survival Rate, Transplantation Conditioning, Transplantation, Autologous, Treatment Outcome

Abstract:

High-dose therapy (HDT) with autologous stem cell transplantation (ASCT) is the standard treatment for patients with chemosensitive relapsed/refractory Hodgkin lymphoma (HL), but this therapy is commonly denied to patients with resistant disease. We explored the utility of HDT and ASCT for chemoresistant HL because there are few established therapies for these patients.